Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancer, today announced that William Ho, Chief Executive Officer and co-founder, will present and host investor meetings at the Jefferies 2019 Global Healthcare Conference being held in New York, NY on June 4-7, 2019. The Incysus Therapeutics presentation is scheduled for Friday, June 7 at 9:00 am Eastern Time.
A webcast of the presentation will be available at the Jefferies 2019 Healthcare Conference website, http://wsw.com/webcast/jeff118/inc/index.aspx and will be available on the Incysus website, www.incysus.com for 90 days following the event.
About Incysus Therapeutics, Inc. Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception, Incysus has received approval of two Investigational New Drug applications (INDs) and has initiated several cancer programs in early preclinical stages, including a checkpoint combination program. The Company’s first program is targeted to treating leukemia and lymphoma with a donor γδ T cell and its second program is targeted to newly-diagnosed glioblastoma (GBM). In collaboration with our academic partners, including the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials in 2019. For more information, visit www.incysus.com.
Forward Looking Statements. Certain statements herein concerning the Company’s future expectations, plans and prospects, including without limitation, the Company’s current expectations regarding its business strategy, product candidates, and clinical development process and timing, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company’s reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.
Contact: Incysus Therapeutics, Inc. +1 646.600.6GDT email@example.com www.incysus.com